The European Union is undergoing one of the most significant pharmaceutical regulatory reforms in more than two decades. The proposed revision of the EU pharmaceutical legislation aims to modernise the regulatory framework, improve patient access to medicines, strengthen supply chain resilience, encourage innovation, and enhance public health protection across Member States.
While much of the discussion has focused on market access, regulatory data protection, and medicine availability, the proposed changes also have important implications for pharmacovigilance (PV) systems and safety monitoring activities.
For Marketing Authorisation Holders (MAHs), Qualified Persons Responsible for Pharmacovigilance (QPPVs), PV service providers, and regulatory teams, understanding these developments is essential for maintaining compliance and preparing for future operational requirements.
The legislation signals a broader shift towards proactive safety monitoring, increased transparency, stronger patient involvement, and greater use of digital technologies in regulatory oversight.
Why Is the EU Reforming Pharmaceutical Legislation?
The current pharmaceutical framework has largely remained unchanged since the early 2000s, despite significant advancements in science, technology, healthcare delivery, and pharmacovigilance.
Since then, the industry has experienced:
- Growth in advanced therapies
- Increased use of real-world evidence
- Expansion of digital health technologies
- Greater patient involvement in healthcare decisions
- More complex global supply chains
- Rising demand for transparency
The revised legislation seeks to create a more modern and adaptable framework capable of addressing these evolving challenges.
For pharmacovigilance teams, this means that safety monitoring is becoming more integrated into the overall lifecycle management of medicinal products.
A Greater Focus on Patient Safety Throughout the Product Lifecycle
Historically, pharmacovigilance activities were often viewed as post-marketing obligations that became more intensive after a product entered the market.
The new legislative proposals reinforce the idea that safety monitoring should be embedded throughout the entire product lifecycle.
This means regulators increasingly expect organisations to continuously assess and manage risks from development through commercialisation and beyond.
The focus is shifting from reactive reporting to proactive safety management.
In practical terms, companies may need stronger systems for:
- Continuous benefit-risk evaluation
- Signal detection and management
- Risk minimisation activities
- Safety communication
- Real-world evidence integration
The expectation is clear: pharmacovigilance should not operate in isolation but as part of a broader quality and regulatory framework.
Increased Use of Real-World Evidence in Safety Monitoring
One of the most significant developments within the proposed legislation is the growing role of real-world evidence (RWE).
Traditionally, safety assessments relied heavily on clinical trial data and spontaneous adverse event reporting.
Today, regulators recognise that valuable safety information can also come from:
- Electronic health records
- Disease registries
- Healthcare databases
- Insurance claims data
- Patient-reported outcomes
- Digital health platforms
As the use of RWE expands, pharmacovigilance teams will need to develop stronger capabilities in data analysis, signal detection, and evidence evaluation.
This does not replace traditional pharmacovigilance methods.
Instead, it creates additional opportunities to identify emerging safety concerns earlier and more effectively.
What This Means for Signal Detection Activities
Signal detection remains one of the most critical functions within pharmacovigilance.
The revised legislation is expected to place greater emphasis on the timely identification, evaluation, and management of safety signals.
Regulators increasingly expect organisations to demonstrate that signal management processes are:
- Risk-based
- Scientifically justified
- Well documented
- Consistently applied
- Supported by appropriate oversight
Companies may face greater scrutiny regarding how signals are prioritised, investigated, and escalated.
A delayed or inadequate response to emerging safety information could have significant regulatory consequences.
Strong signal management processes will become increasingly important as data sources continue to expand.
Enhanced Transparency Requirements
Transparency continues to be a major theme across European healthcare regulation.
Patients, healthcare professionals, and regulators increasingly expect greater visibility into how safety information is collected, assessed, and communicated.
The proposed reforms support this trend by encouraging clearer communication around medicine benefits and risks.
For pharmacovigilance teams, this may lead to increased focus on:
- Safety communication strategies
- Public-facing risk information
- Patient engagement activities
- Benefit-risk transparency
- Regulatory reporting accuracy
Transparency is no longer viewed solely as a regulatory requirement.
It is becoming an essential component of maintaining public trust.
The Growing Role of Digitalisation in Pharmacovigilance
The pharmaceutical industry continues to embrace digital transformation, and pharmacovigilance is no exception.
The new legislation supports the use of modern technologies that can improve efficiency, data quality, and regulatory oversight.
This includes areas such as:
- Electronic reporting systems
- Data analytics platforms
- Artificial Intelligence-assisted processes
- Digital safety monitoring tools
- Automated case processing systems
However, regulators remain clear that technology must be appropriately validated and governed.
Automation does not remove accountability.
Companies must ensure that digital tools support compliance while maintaining data integrity, traceability, and oversight.
Supply Chain Resilience and Its Impact on Pharmacovigilance
Medicine shortages have become a growing concern across Europe.
The proposed legislative reforms include measures designed to strengthen supply chain resilience and improve medicine availability.
While these changes may appear operational, they also have pharmacovigilance implications.
Safety teams may need to become more involved in:
- Product shortage assessments
- Risk communication activities
- Supply disruption management
- Benefit-risk evaluations related to shortages
- Cross-functional decision-making
This reflects the increasingly interconnected nature of quality, regulatory affairs, supply chain management, and pharmacovigilance.
Stronger Expectations for Quality Systems and Oversight
As pharmacovigilance requirements evolve, regulators are placing greater emphasis on governance and oversight.
Companies will be expected to demonstrate that their PV systems remain effective, scalable, and capable of supporting evolving regulatory requirements.
Areas likely to receive increased attention include:
- Pharmacovigilance system governance
- Quality management systems
- Vendor oversight
- Inspection readiness
- Training effectiveness
- Data integrity controls
- Risk management processes
Regulators increasingly want evidence that organisations can identify, investigate, and resolve issues proactively.
Strong governance frameworks will play a critical role in demonstrating compliance.
How Pharmacovigilance Teams Should Prepare
Although elements of the legislation are still progressing through the EU legislative process, organisations should begin evaluating their readiness now.
Practical preparation steps include:
Review Current PV Systems
Assess whether existing processes can support evolving regulatory expectations.
Strengthen Signal Management Frameworks
Ensure signal detection and evaluation processes are robust, documented, and risk-based.
Evaluate Data Sources
Identify opportunities to incorporate real-world evidence and additional safety data sources.
Enhance Digital Readiness
Review technology platforms, automation tools, and data governance controls.
Improve Cross-Functional Collaboration
Strengthen collaboration between pharmacovigilance, regulatory affairs, quality, medical affairs, and supply chain teams.
Invest in Training
Ensure personnel understand emerging regulatory expectations and their potential impact on daily activities.
The organisations that prepare early are often better positioned to adapt as regulatory requirements become finalised.
What the New Legislation Signals for the Future of Pharmacovigilance
The proposed EU pharmaceutical reforms demonstrate that pharmacovigilance is becoming increasingly proactive, data-driven, and integrated across the medicinal product lifecycle.
Future PV systems are likely to place greater emphasis on:
- Continuous safety monitoring
- Real-world evidence utilisation
- Data analytics and digital tools
- Patient engagement
- Risk-based decision-making
- Transparency and communication
- Cross-functional collaboration
Rather than simply collecting adverse event reports, pharmacovigilance teams will increasingly be expected to generate meaningful insights that support patient safety and informed healthcare decisions.
The role of PV professionals is expanding from compliance management towards strategic risk management.
Preparing for the Future with Quality & Vigilance Ltd.
As the EU pharmaceutical landscape continues to evolve, organisations need practical strategies that align pharmacovigilance activities with emerging regulatory expectations. The proposed reforms are expected to influence not only safety reporting requirements but also signal management, governance, transparency, digitalisation, and lifecycle risk management.
Quality & Vigilance Ltd. (Q&V) supports pharmaceutical, biotechnology, and healthcare organisations with pharmacovigilance, regulatory affairs, quality assurance, auditing, inspection readiness, and compliance management services. By helping organisations strengthen PV systems, improve governance frameworks, enhance inspection preparedness, and adapt to evolving regulatory requirements, Q&V enables businesses to maintain compliance while supporting patient safety objectives.
Support areas include:
- Pharmacovigilance system development and optimisation
- QPPV support and oversight
- Signal detection and risk management
- PV audits and inspection readiness
- Regulatory compliance and governance
- Vendor qualification and oversight
- Safety reporting process improvement
- Training and competency development
- Quality management system integration
- Continuous compliance and risk-based monitoring
As regulatory expectations continue to evolve, organisations that invest in robust pharmacovigilance systems, strong governance structures, and proactive compliance strategies will be better positioned to navigate future requirements and protect patient safety across global markets.